Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer

Nobuhiko Arai, Hikaru Sasaki, Ryota Tamura, Kentaro Ohara, Kazunari Yoshida

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Glioblastoma (GBM) is a lesion radiologically characterized by magnetic resonance imaging findings, such as ring enhancement with extensive perifocal edema and a butterfly appearance extending into the bilateral lobes. However, these characteristic findings could be changed by antiangiogenic therapy, with decreased contrast enhancement and improved perifocal edema. Herein, we report a case of GBM that arose during treatment with a tyrosine kinase inhibitor for another cancer. Case Description: A 57-year-old man presented with seizures. Until the seizure onset, he had been treated with the multireceptor tyrosine kinase inhibitor lenvatinib for 4 years for thyroid cancer and its metastasis to the thoracic vertebral body. Magnetic resonance imaging revealed a slightly high intensity lesion in the left frontal base area on T2-weighted or fluid-attenuated inversion recovery images, and the lesion showed only faint enhancement on T1-weighted images after gadolinium administration. Total resection was performed and the histopathologic diagnosis was GBM. However, grade IV histology was observed in only a limited area, and most of the specimen showed lower grade histology with moderate vascularization that lacked microvascular proliferation. Conclusions: Lenvatinib, which is antiangiogenic, might have affected the radiologic characteristics, as well as the pathology of the tumor. Brain tumors arising during treatment with receptor tyrosine kinases for other cancers could show atypical imaging findings.

Original languageEnglish
JournalWorld Neurosurgery
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Glioblastoma
Thyroid Neoplasms
Magnetic Resonance Imaging
Protein-Tyrosine Kinases
Edema
Histology
Seizures
Neoplasms
Butterflies
Gadolinium
Receptor Protein-Tyrosine Kinases
Brain Neoplasms
Thorax
Therapeutics
Pathology
Neoplasm Metastasis
lenvatinib

Keywords

  • Antiangiogenic therapy
  • Glioblastoma
  • Lenvatinib
  • Magnetic resonance imaging
  • Receptor tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

@article{e6fa44e130ed4a399599505613552ed3,
title = "Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer",
abstract = "Background: Glioblastoma (GBM) is a lesion radiologically characterized by magnetic resonance imaging findings, such as ring enhancement with extensive perifocal edema and a butterfly appearance extending into the bilateral lobes. However, these characteristic findings could be changed by antiangiogenic therapy, with decreased contrast enhancement and improved perifocal edema. Herein, we report a case of GBM that arose during treatment with a tyrosine kinase inhibitor for another cancer. Case Description: A 57-year-old man presented with seizures. Until the seizure onset, he had been treated with the multireceptor tyrosine kinase inhibitor lenvatinib for 4 years for thyroid cancer and its metastasis to the thoracic vertebral body. Magnetic resonance imaging revealed a slightly high intensity lesion in the left frontal base area on T2-weighted or fluid-attenuated inversion recovery images, and the lesion showed only faint enhancement on T1-weighted images after gadolinium administration. Total resection was performed and the histopathologic diagnosis was GBM. However, grade IV histology was observed in only a limited area, and most of the specimen showed lower grade histology with moderate vascularization that lacked microvascular proliferation. Conclusions: Lenvatinib, which is antiangiogenic, might have affected the radiologic characteristics, as well as the pathology of the tumor. Brain tumors arising during treatment with receptor tyrosine kinases for other cancers could show atypical imaging findings.",
keywords = "Antiangiogenic therapy, Glioblastoma, Lenvatinib, Magnetic resonance imaging, Receptor tyrosine kinase inhibitor",
author = "Nobuhiko Arai and Hikaru Sasaki and Ryota Tamura and Kentaro Ohara and Kazunari Yoshida",
year = "2017",
doi = "10.1016/j.wneu.2017.08.017",
language = "English",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer

AU - Arai, Nobuhiko

AU - Sasaki, Hikaru

AU - Tamura, Ryota

AU - Ohara, Kentaro

AU - Yoshida, Kazunari

PY - 2017

Y1 - 2017

N2 - Background: Glioblastoma (GBM) is a lesion radiologically characterized by magnetic resonance imaging findings, such as ring enhancement with extensive perifocal edema and a butterfly appearance extending into the bilateral lobes. However, these characteristic findings could be changed by antiangiogenic therapy, with decreased contrast enhancement and improved perifocal edema. Herein, we report a case of GBM that arose during treatment with a tyrosine kinase inhibitor for another cancer. Case Description: A 57-year-old man presented with seizures. Until the seizure onset, he had been treated with the multireceptor tyrosine kinase inhibitor lenvatinib for 4 years for thyroid cancer and its metastasis to the thoracic vertebral body. Magnetic resonance imaging revealed a slightly high intensity lesion in the left frontal base area on T2-weighted or fluid-attenuated inversion recovery images, and the lesion showed only faint enhancement on T1-weighted images after gadolinium administration. Total resection was performed and the histopathologic diagnosis was GBM. However, grade IV histology was observed in only a limited area, and most of the specimen showed lower grade histology with moderate vascularization that lacked microvascular proliferation. Conclusions: Lenvatinib, which is antiangiogenic, might have affected the radiologic characteristics, as well as the pathology of the tumor. Brain tumors arising during treatment with receptor tyrosine kinases for other cancers could show atypical imaging findings.

AB - Background: Glioblastoma (GBM) is a lesion radiologically characterized by magnetic resonance imaging findings, such as ring enhancement with extensive perifocal edema and a butterfly appearance extending into the bilateral lobes. However, these characteristic findings could be changed by antiangiogenic therapy, with decreased contrast enhancement and improved perifocal edema. Herein, we report a case of GBM that arose during treatment with a tyrosine kinase inhibitor for another cancer. Case Description: A 57-year-old man presented with seizures. Until the seizure onset, he had been treated with the multireceptor tyrosine kinase inhibitor lenvatinib for 4 years for thyroid cancer and its metastasis to the thoracic vertebral body. Magnetic resonance imaging revealed a slightly high intensity lesion in the left frontal base area on T2-weighted or fluid-attenuated inversion recovery images, and the lesion showed only faint enhancement on T1-weighted images after gadolinium administration. Total resection was performed and the histopathologic diagnosis was GBM. However, grade IV histology was observed in only a limited area, and most of the specimen showed lower grade histology with moderate vascularization that lacked microvascular proliferation. Conclusions: Lenvatinib, which is antiangiogenic, might have affected the radiologic characteristics, as well as the pathology of the tumor. Brain tumors arising during treatment with receptor tyrosine kinases for other cancers could show atypical imaging findings.

KW - Antiangiogenic therapy

KW - Glioblastoma

KW - Lenvatinib

KW - Magnetic resonance imaging

KW - Receptor tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85028726884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028726884&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2017.08.017

DO - 10.1016/j.wneu.2017.08.017

M3 - Article

C2 - 28804045

AN - SCOPUS:85028726884

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -